B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
ANTX
AN2 TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+32.2
Score
AI commentary
Sentiment remains cautious-neutral. Company sources verified in March and April support better runway and a fuller 2026 catalyst calendar, but the deterministic prior is still negative and the follow-up earnings check did not surface a new May 2026 company release or delayed analyst revision as of 2026-05-04, so there is no clear post-print thesis upgrade to underwrite. The stock still looks like a low-coverage milestone-monitoring biotech where financing mechanics and execution timing matter more than near-term fundamental revision [#IR-2026-03-17] [#8-K-2026-04-09] [#IR-2026-05-04].
RankAlpha Sentiment Codex - 2026-05-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystATM capacity offsets runway support with renewed dilution overhangHigh impact
AN2 added an $80 million Jefferies at-the-market facility on April 9, 2026 after its March 2026 $40 million private placement, which supports liquidity but reintroduces supply risk for a micro-cap stock already trading on financing sensitivity [#8-K-2026-04-09] [#IR-2026-03-09] [#IR-2026-03-17].
2026-09-30eventPolycythemia vera Phase 2 start remains the nearest company-controlled clinical milestoneHigh impact
Management said oral epetraborole's Phase 2 proof-of-concept study in polycythemia vera is expected to begin in India in 3Q26, with periodic data readouts possible as early as 4Q26, making this the clearest nearer-term upside proof point if execution stays on schedule [#IR-2026-03-17] [#10-K-2026-03-17].
2027-12-31catalystM. abscessus Phase 2 IIT has begun screening but value realization is pushed to late 2027High impact
AN2 announced initiation of the 84-patient investigator-initiated Phase 2 trial in M. abscessus lung disease, with patient screening underway and topline data planned for late 2027; the study adds meaningful optionality but still leaves a long execution window and limited near-term readthrough [#IR-2026-03-31] [#IR-2026-03-17].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology